Research programme: asthma VPAC2 receptor agonists - Forbes Medi-Tech

Drug Profile

Research programme: asthma VPAC2 receptor agonists - Forbes Medi-Tech

Alternative Names: FM-TP3000

Latest Information Update: 27 May 2008

Price : $50

At a glance

  • Originator Forbes Medi-Tech
  • Class
  • Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Pulmonary arterial hypertension

Most Recent Events

  • 27 May 2008 Discontinued - Preclinical for Asthma in Canada (unspecified route)
  • 27 May 2008 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Canada (unspecified route)
  • 27 May 2008 Discontinued - Preclinical for Pulmonary hypertension in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top